Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant ...

Figure 1: Key signaling pathways and targeted factors ... several major pathways involved in breast cancer, including PI3K/Akt/mTOR, RAS/RAF/MEK/ERK, HER2, Wnt/β-catenin, Notch, NF-κB, and ...

The review highlights how certain gene mutations and disrupted signaling pathways influence ... involved in breast cancer, including PI3K/Akt/mTOR, RAS/RAF/MEK/ERK, HER2, Wnt/β-catenin, Notch ...

In the near future, oncologists should be able to identify and manage cardiac risks, both in clinical trials and daily practice. Many successful agents – including anthracyclines and trastuzumab ...

What Is HER2-Positive Breast Cancer? HER2-positive breast cancer is when breast cancer cells have a protein receptor called human epidermal growth factor receptor 2 (HER2). Normally, this protein ...

Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer. All patients with breast ... therapy in patients that have alterations in ...

HER2-negative and HER2-positive are types of breast cancer that share some things in common, but they have plenty of differences, too. Which kind you have can affect the treatment you get.